Mineralys Therapeutics (MLYS) Retained Earnings (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Retained Earnings data on file, last reported at -$496.5 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 44.03% year-over-year to -$496.5 million; the trailing twelve-month figure through Mar 2026 stood at -$496.5 million (down 44.03% YoY), and the FY2025 full-year result was $1.1 billion, up 123.56% from the prior year.
• Retained Earnings eased to -$496.5 million in Q1 2026, from $1.1 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $1.1 billion in Q4 2025 to a low of -$496.5 million in Q1 2026.
• A 5-year average of $191.5 million and a median of $155.8 million in 2022 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings surged 840.45% in 2024 and sank 171.19% in 2025, its largest moves.
• Tracing MLYS's Retained Earnings over 5 years: stood at -$52.8 million in 2022, then jumped by 792.78% to $365.9 million in 2023, then soared by 34.96% to $493.8 million in 2024, then soared by 123.56% to $1.1 billion in 2025, then sank by 144.98% to -$496.5 million in 2026.
• Business Quant data shows MLYS's Retained Earnings at -$496.5 million in Q1 2026, $1.1 billion in Q4 2025, and $1.0 billion in Q3 2025.